Rouy D, Grailhe P, Nigon F, Chapman J, Anglés-Cano E
Unité 143, Hôpital de Bicêtre, France.
Arterioscler Thromb. 1991 May-Jun;11(3):629-38. doi: 10.1161/01.atv.11.3.629.
Apoprotein(a), (apo[a]), the specific antigen of lipoprotein(a) (Lp[a]), consists of structural domains (a serine protease unit, kringles 4 and 5) with marked homology to those of the corresponding domains in plasminogen. In this study, we have investigated the impact of this unique structural mimicry on the binding and activation of plasminogen by fibrin-bound tissue-type plasminogen activator at the plasma-fibrin interface. We found that the total amount of plasmin generated on the surface of fibrin was decreased in the presence of high concentrations of Lp(a): 197 +/- 65 fmol in plasmas with greater than 60 mg/dl Lp(a) versus 287 +/- 112 fmol in control plasmas. A similar effect was also apparent in the corresponding euglobulin fractions (554 +/- 169 fmol versus 754 +/- 310 fmol), the latter lacking the plasminogen-binding proteins alpha 2-antiplasmin and histidine-rich glycoprotein, but containing Lp(a). The difference between plasma samples was significant (p less than 0.05) as calculated from the percent decrease in plasmin generated from plasmas with high levels of Lp(a) relative to that generated in the paired controls with low Lp(a) levels. The involvement of Lp(a) was verified in a reconstituted system consisting of normal human plasma supplemented with 100 mg/dl of either purified Lp(a) or low density lipoprotein. Lp(a) produced a decrease of 30% in the generation of plasmin (180 fmol versus 255 fmol in plasma, and 485 fmol versus 705 fmol in the euglobulin fraction). Moreover, using a radiolabeled sheep antibody against human apo(a), we were able to demonstrate the binding of 40 fmol Lp(a) to fibrin during ongoing plasminogen activation. These results indicate that Lp(a) impairs the binding of plasminogen to fibrin and thereby decreases the generation of plasmin by occupying C-terminal lysine residues unveiled on the fibrin surface by plasmin degradation as recently reported (Circulation 1990;82[suppl III]:III-92). In consequence, impairment of fibrinolysis and accumulation of Lp(a) at sites of vascular injury may occur, factors that may be important in the development of atherosclerosis and associated thrombosis.
载脂蛋白(a)(apo[a])是脂蛋白(a)(Lp[a])的特异性抗原,由一些结构域(一个丝氨酸蛋白酶单位、kringle 4和kringle 5)组成,这些结构域与纤溶酶原中相应结构域具有显著同源性。在本研究中,我们探讨了这种独特的结构模拟对血浆-纤维蛋白界面上纤维蛋白结合的组织型纤溶酶原激活物介导的纤溶酶原结合及激活的影响。我们发现,在高浓度Lp(a)存在时,纤维蛋白表面产生的纤溶酶总量减少:Lp(a)大于60 mg/dl的血浆中为197±65 fmol,而对照血浆中为287±112 fmol。在相应的优球蛋白组分中也有类似的效应(分别为554±169 fmol和754±310 fmol),后者缺乏纤溶酶原结合蛋白α2-抗纤溶酶和富含组氨酸的糖蛋白,但含有Lp(a)。根据高Lp(a)水平血浆中产生的纤溶酶相对于低Lp(a)水平配对对照血浆中产生的纤溶酶减少的百分比计算,血浆样本之间的差异具有统计学意义(p<0.05)。在一个由补充了100 mg/dl纯化Lp(a)或低密度脂蛋白的正常人血浆组成的重组系统中,证实了Lp(a)的参与。Lp(a)使纤溶酶的产生减少了30%(血浆中分别为180 fmol和255 fmol,优球蛋白组分中分别为485 fmol和705 fmol)。此外,使用一种针对人apo(a)的放射性标记绵羊抗体,我们能够证明在纤溶酶原持续激活过程中有40 fmol Lp(a)与纤维蛋白结合。这些结果表明,Lp(a)损害了纤溶酶原与纤维蛋白的结合,从而通过占据纤溶酶降解在纤维蛋白表面暴露的C末端赖氨酸残基而减少了纤溶酶的产生,正如最近报道的那样(《循环》1990年;82[增刊III]:III-92)。因此,可能会发生纤维蛋白溶解受损和Lp(a)在血管损伤部位的积聚,这些因素在动脉粥样硬化和相关血栓形成的发展中可能很重要。